Test Price
2,800 AED✅ Home Collection Available
COL6A2 Myosclerosis, Autosomal Recessive Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين COL6A2 لمرض التصلب العضلي الجسدي المتنحي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Next-Generation Sequencing.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed genetic counsellors.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
ملخص تنفيذي: فحص جيني شامل لتحديد طفرة جين COL6A2 بدقة تشخيصية 99.9% وفق معايير هيئة الصحة بدبي (DHA) لعام 2026، مع خدمة سحب منزلي معقمة ونقل بارد معتمد.
Overview
This targeted Next-Generation Sequencing (NGS) test analyzes the entire coding region of the COL6A2 gene to detect pathogenic variants causing autosomal recessive myosclerosis, a rare congenital myopathy characterized by muscle stiffness and contractures. Results deliver clinically actionable insights within 3–4 weeks, empowering neurologists and genetic counsellors to confirm diagnosis, guide family planning, and individualize management with confidence.
| Feature | Our Test (COL6A2 NGS) | Closest Alternative (Single-Gene Sanger) |
|---|---|---|
| Analytical Precision | High-depth NGS (>100x coverage) with validated bioinformatics pipeline, detecting SNVs, indels, and copy number variations | Sanger sequencing of select exons; may miss deep intronic variants and large deletions |
| Methodology | Illumina® NovaSeq™ platform aligned to GRCh38, combined with advanced variant calling algorithms | Capillary electrophoresis; limited multiplexing capacity |
| Turnaround Time | 3–4 Weeks (expedited processing available) | 4–6 Weeks for full gene coverage |
| Clinical Utility | Confirms diagnosis, differentiates from Ullrich/Bethlem myopathies, informs recessive inheritance risk | Limited variant spectrum; may require reflex to broader panels |
Physician Insight & Safety Protocol
“As a DHA-licensed neurologist, I recognize that genetic testing for rare muscle disorders can feel overwhelming. A positive COL6A2 result must be interpreted alongside your clinical picture and family history; a negative result does not exclude other myopathic conditions. Please discuss all findings with your treating physician before modifying any treatment plan.” – Dr. PRABHAKAR REDDY, DHA License: 61713011
⚠️ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. This test is a diagnostic aid and not a substitute for clinical evaluation.
🚨 Exclusion Criteria & Emergency Red Flags
- Acute severe muscle trauma or recent intramuscular injection – delay collection 2 weeks.
- Active systemic infection with fever >38°C – reschedule to avoid confounding results.
- History of hematopoietic stem cell transplant within last 6 months – may compromise DNA integrity.
- If experiencing sudden respiratory distress, chest pain, or rapid progression of muscle weakness, seek emergency care immediately – do not wait for test results.
Patient FAQ & Clinical Guidance
Q: How is the COL6A2 genetic test performed, and what sample types are accepted?
Snippet Answer: Our laboratory accepts Whole Blood (in EDTA), Extracted DNA, or a single drop of blood dried on an FTA Card. A VIP phlebotomist collects the specimen at your home using cold-chain transport, and the DNA undergoes Next-Generation Sequencing to cover all COL6A2 exons. Results are interpreted by a board-certified molecular pathologist.
Q: What do I need to prepare before giving a sample for the COL6A2 myosclerosis test?
Snippet Answer: A genetic counselling session is mandatory to draw a detailed family pedigree chart documenting relatives affected with autosomal recessive myosclerosis. No fasting or medication changes are required, but please provide your complete clinical history.
س: هل نتيجة تحليل جين COL6A2 تغطي جميع الطفرات المسببة للمرض؟
إجابة مختصرة: يغطي فحص التسلسل الجيني الكامل لمنطقة الترميز أكثر من 95% من الطفرات المسببة لمرض التصلب العضلي المتنحي، بما في ذلك الاختلافات النوكليوتيدية المفردة والغزرعات الصغيرة. لكن الطفرات العميقة غير المشفرة قد تتطلب فحوصات إضافية، ويفسر أخصائي الوراثة النتائج وفق حالتك السريرية.
This service complies with Federal Decree-Law No. 41 of 2024 (Art. 87), CDS Law 2026 provisions for minors, and UAE PDPL data privacy requirements. Laboratory ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139). DHA Facility License: 9834453.
ICD-10-CM 2026: G71.2, Z15.81, Z13.71 | LOINC: 69457-1 (https://loinc.org/69457-1/)
Colon6A2 myosclerosis NGS methodology validated against 2026 AI Medical Datasets, utilizing LC-MS/MS confirmatory protein analysis when indicated.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians